Kodiak Sciences Faces Critical Test as Losses Mount and Analyst Confidence Wavers

Kodiak Sciences Inc reports fourth-quarter 2025 earnings on March 26, 2026. With the biotech company expected to post another quarterly loss and recent earnings history marked by persistent misses, investors will be watching closely for signs of progress toward profitability. The stock has weakened significantly in recent weeks, trading well below key technical levels as Wall Street's outlook grows increasingly uncertain.

Part 1: Earnings Preview

Kodiak Sciences Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, including age-related macular degeneration and diabetic retinopathy. The company's lead product candidate utilizes its proprietary antibody biopolymer conjugate platform technology.

Kodiak is expected to report fourth-quarter 2025 results on March 26, with analysts forecasting a loss of $1.02 per share based on consensus from 4 analysts. The most recently reported quarter (Q3 2025) showed a loss of $1.16 per share. Compared to the same quarter last year when the company lost $0.84 per share, the current estimate represents a 21.43% deterioration year-over-year, reflecting mounting losses as the company continues its clinical development programs.

Three key themes define this earnings story:

Clinical Trial Progress and Regulatory Pathway: Investors will scrutinize any updates on the company's pivotal clinical trials and regulatory interactions with the FDA. The timeline to potential commercialization remains the critical driver of long-term value, and any delays or setbacks could significantly impact investor sentiment.

Cash Burn and Runway: With widening losses, the company's cash position and burn rate are under intense focus. Analysts will be looking for guidance on how long current resources can fund operations and whether additional capital raises may be necessary, which could dilute existing shareholders.

Competitive Landscape Dynamics: The retinal disease treatment market is increasingly crowded, with both established players and emerging biotechs vying for market share. How Kodiak differentiates its platform technology and maintains competitive advantages will be crucial to its investment thesis.

Analyst commentary ahead of the release reflects caution, with estimates having been revised downward from a prior consensus of $0.84 to the current $1.02 loss expectation. The range of estimates spans from a loss of $0.86 to $1.17, indicating some uncertainty about the quarter's outcome.

Part 2: Historical Earnings Performance

Kodiak Sciences has struggled with earnings execution over the past year, consistently missing analyst expectations. The company's recent track record shows three misses in the last four quarters, with only one modest beat.

The most recent quarter (September 2025) saw the company report a loss of $1.16 per share against expectations of $1.07, representing an 8.41% miss. This followed a June 2025 report that came in at a loss of $1.03 versus estimates of $1.01 (a 1.98% miss). The March 2025 quarter was particularly disappointing, with a reported loss of $1.09 against expectations of just $0.89—a substantial 22.47% miss that likely rattled investor confidence. The only bright spot came in December 2024, when the company beat estimates by 6.67%, reporting a loss of $0.84 versus the expected $0.90.

The pattern reveals a company whose losses are deepening faster than analysts anticipated, with the magnitude of misses accelerating in recent quarters. This trend of deteriorating performance relative to expectations suggests either overly optimistic analyst projections or operational challenges that are proving more difficult to overcome than initially forecast.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Kodiak Sciences typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around Kodiak's earnings releases shows significant volatility, with an average absolute Day 0 move of 6.27% and Day +1 move of 7.69%. The stock has demonstrated particularly dramatic reactions in several recent quarters, including a catastrophic 29.40% decline on earnings day in March 2024, followed by an additional 15.40% drop the next session. More recently, the November 2025 report triggered a 6.81% decline on Day 0, though the stock recovered with a 3.39% gain the following day. The August 2025 earnings saw muted Day 0 action (up just 1.17%) but a powerful 16.47% surge on Day +1, suggesting positive surprises can generate substantial follow-through. Trading ranges are wide, averaging 9.51% on Day 0 and 14.42% on Day +1, reflecting the high-stakes nature of clinical-stage biotech earnings where single data points can dramatically shift the investment narrative.

Part 2.2: Options Market Expected Move

The options market is pricing in an expected move of 19.80% through the April 17 expiration, significantly higher than the stock's average historical Day 0 move of 6.27% and even exceeding the average Day +1 move of 7.69%. This elevated implied volatility suggests options traders are anticipating a potentially outsized reaction to this earnings report, possibly reflecting heightened uncertainty around clinical updates or financial guidance.

Part 3: What Analysts Are Saying

Analyst sentiment on Kodiak Sciences presents a mixed picture with a consensus leaning cautiously optimistic. The average analyst recommendation stands at 3.89 out of 5.0, which translates to a rating between Hold and Buy. Among the 9 analysts covering the stock, 5 rate it a Strong Buy, while 3 maintain Hold ratings and 1 has assigned a Strong Sell rating. Notably, there are no Moderate Buy or Moderate Sell ratings, suggesting analysts have relatively polarized views on the stock's prospects.

The consensus has remained unchanged over the past month, with the same distribution of ratings and identical average recommendation of 3.89. This stability suggests analysts are waiting for the upcoming earnings release and any accompanying clinical or regulatory updates before adjusting their stances.

The average price target of $32.86 implies 44.5% upside from the current price of $22.75, indicating analysts collectively believe the stock is undervalued at current levels. However, the wide range of price targets—from a low of $14.00 to a high of $50.00—underscores the significant uncertainty surrounding the company's valuation. The low-end target suggests potential downside of 38.5%, while the high-end target implies upside of 120%, reflecting the binary nature of clinical-stage biotech investing where outcomes can vary dramatically based on trial results and regulatory decisions.

Part 4: Technical Picture

Kodiak Sciences enters earnings in a weakening technical position, with the Barchart Technical Opinion deteriorating sharply in recent weeks. The signal currently stands at Buy (24%), down from Buy (40%) last week and a much stronger Buy (88%) a month ago. This rapid decline in technical strength suggests mounting selling pressure and fading momentum as the earnings date approaches.

Timeframe Analysis:

• Short-term (Hold): Neutral signal indicates near-term momentum has stalled after recent weakness
• Medium-term (50% Buy): Moderate buy signal suggests some intermediate-term support remains intact
• Long-term (50% Buy): Moderate buy signal reflects the stock's longer-term uptrend from lower levels earlier in the cycle

Trend Characteristics: The current trend is characterized as Weak with Weakest direction, indicating deteriorating momentum and vulnerability heading into the earnings event.

The stock is trading at $22.75, positioned below most key moving averages. The price sits below the 10-day ($22.80), 20-day ($24.44), 50-day ($24.84), and 100-day ($24.10) moving averages, though it remains above the 200-day moving average at $16.73. This configuration—below short- and intermediate-term averages but above the long-term trend line—suggests the stock is in a corrective phase within a broader uptrend.

The technical setup heading into earnings is cautionary. With the stock trading below multiple resistance levels and technical momentum weakening significantly, Kodiak lacks the technical cushion that might absorb a disappointing report. The 20-day moving average at $24.44 represents immediate overhead resistance, while the 50-day at $24.84 marks a more significant hurdle. On the downside, a break below the recent lows near $22.35 (the 5-day moving average) could trigger accelerated selling, with the 200-day moving average at $16.73 serving as major support. The deteriorating technical picture combined with elevated options-implied volatility suggests traders are bracing for significant post-earnings movement in a stock that's already under pressure.